ArticleClinical and molecular hepatology2025

Correspondence to editorial 1 on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial".

Sung Hwan Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.